BASEL, Switzerland, Oct. 4 /PRNewswire-FirstCall/ –
Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) Pursuant to
the company’s press release issued the 30th of September 2010, the
following is a brief review and explanation of the earlier
statements concerning the first of many Neuro-Biotech’s licensed
products, “SymPath(R) blood test”.
For a better understanding, an “in vitro” blood test is
described as, a non evasive test, whereas the testing, as in the
case of SymPath(R), is performed on a small amount of the patient’s
blood. To date the SymPath(R) blood test has been tested on several
thousand of patients whose results illustrate a success rate
accuracy of 98.8%. The testing audits have been rigorously
documented and have met every industry standard.
SymPath(R) is an indispensable tool with unprecedented results.
Medical practitioners have long been waiting for a similar test to
accurately and quantifiably diagnose those symptoms amongst
patients as, depression and stress related disorders. What does
this mean for physicians?
Firstly, SymPath(R) assists the medical practitioner in
diagnosing patients, based on quantitative measurement, as precise
as current cholesterol tests. SymPath(R) allows the medical
practitioner to determine with accuracy the severity level of the
patient’s anxiety or depressive state. The medical practitioner
will now be able to state, based on an objective quantified
measure, using this test, rather than subjectively determining the
diagnosis, as is currently performed.
Furthermore SymPath(R) will eliminate the costly and highly
inefficient trial and errors currently performed by physicians in
prescribing their recommended remedy, which can waste time and
further cause harm for both patients and physicians. For instance,
patients suffering from depression or stress related disorders will
now properly diagnosed immediately following the testing through
Neuro-Biotech’s SymPath(R) test.
No more g
‘/>”/>
